Albany

At PRI, we are harnessing the versatility of nanotechnology and biotechnology (sometimes called nanobiotechnology) in formulating nanoparticles that can benefit humanity by formulating nanoparticles targeted directly to a tumor site or other specific organ within the body and carry a payload of potent drug molecule(s) for treatment.

Nanobiotechnology for Early Detection and Treatment

• Early detection of different tumor types using nanotechnology-based imaging techniques
• Targeted delivery of chemotherapeutic agent-loaded nanoparticles for pancreatic, brain, breast, prostate, ovarian, lung, and other cancer types
• Nano-encapsulation of various natural products for improved pharmacokinetics and pharmacodynamics
• Conjugation of different targeting agents on nanoparticles’ surface to improve efficacy and safety, such as nanoparticle thyroid agonists and antagonists
• Nano-targeted delivery to cancer cells and associated cancer stem cells

PRI Drug Discovery Areas Using Nanobiotechnology Platforms

• Cardiovascular and vascular diseases
  • Regional Atherothrombosis Working Group (ACPHS, AMC, SUNY Nano Sciences, RPI, Wadsworth, and VA at Albany) in Atherosclerosis/Thrombosis toward the establishment of Center for Innovation in the early detection, prevention, and treatment of Atherothrombosis
• Ophthalmology-related disorders
  • Development of novel angiogenesis inhibitors for the suppression of retinal and choroidal neovascularization for the treatment of diabetic retinopathy and age-related macular degeneration
• Oncology and Hematological disorders
• Inflammatory diseases
  • Development of novel therapy for acute and chronic inflammatory disorders
• Neurological disorders
  • Targeted delivery of novel target for neurological disorders

PRI Drug Development Areas Using Nanobiotechnology Platforms

• Nanoformulation and drug delivery
  • Reformulation of existing generic pharmaceuticals
  • Nanoformulation of new drug targets